Achilles Therapeutics (ACHL) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, with an additional $12.8 million received as a cash R&D tax credit in October. The company is seeking strategic options with BofA Securities following the discontinuation of its TIL-based cNeT program. Financial highlights reveal a net loss of $19.6 million for the third quarter, reflecting increased R&D expenses compared to the previous year.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.
